The type III TGF-β receptor suppresses breast cancer progression
J. Clin. Invest. Mei Dong, et al. 117:206 doi:10.1172/JCI29293 [
Go to this article.]
Figure 4TβRIII delayed and decreased metastatic potential of breast cancer cells in vivo. Either 4T1-Neo (Neo) or 4T1-TβRIII (RIII) cells (75,000 cells/mouse) were implanted into the axillary mammary fat pads of BALB/c mice. (
A) Primary tumor growth was recorded by measuring tumor size every 2 days beginning at 10 days after injection and presented as mean ± SEM. (
B) Weight of the primary tumors upon surgical removal on day 20 after injection. Data are mean ± SEM (
n = 16). (
C) Bioluminescence imaging was performed every 3 postoperative days (POD). Representative images are shown. Red and violet signals correspond to the maximum and minimum intensity values, respectively, with other colors representing the values in between. (
D) Record of luminescent signals for every mouse in each group at the indicated time points. (
E) Average luminescent signal in each group at the indicated time points. **
P < 0.01.
